Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 2Thymoma 1Stomach Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × vorolanib × Clear all
NCT03511222 2020-07-29

Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors

Washington University School of Medicine

Phase 1 Terminated
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡